News
-
-
-
PRESS RELEASE
Fresenius acquires remaining 45% of mAbxience for up to €750 million, taking full ownership of its biosimilars platform
Fresenius SE & Co. KGaA acquires remaining 45% of mAbxience for up to €750 million, strengthening biosimilars platform and competitive position in fast-growing market -
-
-
-
-
-
-